4D Molecular Therapeutics, Inc. Financials

Market Capitalization $196.4 Million as of July 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-1.81
Forward PE	-1.48
Price to Sales TTM	$13242.88
Price to Book MRQ	$0.68
Enterprise to Revenue	-0.45
Enterprise to EBITDA	0.09

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	-1704400.00%
Return on Assets TTM	-29.67%
Return on Equity TTM	-32.76%

Income Statement

Revenue TTM	$17,000
Revenue per Share TTM	$0.53
Quarterly Revenue Growth	-100.00%
Gross Profit TTM	$-97,079,000
EBITDA	$-163,692,000
Net Income to Common TTM	$-143,480,000
Diluted EPS TTM	$-2.85
Quarterly Earnings Growth YoY	-99.99%

Balance Sheet

Total Cash MRQ	$0
Total Cash per Share MRQ	$
Total Debt MRQ	$
Total Debt to Equity MRQ	2.32
Current Ratio MRQ	17.33
Book Value per Share MRQ	$7.15

Cash Flow

Operating Cash Flow TTM	$-76,765,000
Levered Free Cash Flow TTM	$-100,837,000

FDMT Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	46,227,700
Float Shares	25,284,302
Avg 10 Volume	744,820
Avg 30 Volume	None
Shares Short	7,986,854
Short Ratio	7.94
Short % of Shares	17.98%
% Held by Insiders	3.91%
% Held by Institutions	112.62%

Stock Price Summary

Beta
Fifty Two Week Low	$4.43
Fifty Two Week High	$36.25
Fifty Two Week Change	-286.70%
Day 50 MA	$6.60
Day 200 MA	$15.38

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date